


*Pseudomonas aeruginosa* w/o Piperacillin Tazobactam



*Pseudomonas aeruginosa* with Piperacillin Tazobactam

# Detecting Antimicrobial Resistance: The Silent Pandemic

-  
**AMR in other bacteria**

**Prof. Adrian Egli, MD PhD**  
Institute for Medical Microbiology, University of Zurich


25.10.2022

Email: [aegli@imm.uzh.ch](mailto:aegli@imm.uzh.ch)  
 @AppliedMicrobi2




# The Lenski experiment: a world of variants

- > 25 years of *E. coli* in culture with more than 60'000 passages
- Stochastical element of evolution




# The mega plate: visualize real-time evolution



Agarplate with increasing concentration of an antibiotic (Trimethoprim)

Baym M et al. Science 2016


# Rapid evolution against antibiotics



Resistance against very high antibiotic concentrations within 2 weeks


Adapted from Baym M et al. Science 2016

# Evolution through point mutations



Baym M et al. Science 2016

# Evolution through point mutations



1. Training required:  
**Step wise increase!**



2. Many ways lead to  
Rome: **many ways to  
resistance!**




Baym M et al. Science 2016

# Acquisition of antibiotic resistance


## Mechanisms of mobile antibiotic resistance

Pathogenic bacteria can acquire antibiotic resistance (ABR) genes through two main mechanisms of horizontal gene transfer (HGT): conjugation and transduction. Compensatory mutations alleviate the fitness costs imposed by ABR genes, contributing to their stabilization. CRISPR-Cas-based systems may selectively destroy DNA carrying mobile ABR genes.



MacLean RC et al, Science 2019


# Resistance mechanisms basics




- 1. **efflux pump**
- 2. **porin loss**
- 3. **target modification**
- 4. **enzymatic cleavage**

Peleg AY et Hooper DC; New Engl J Med 2010

# Antibioticaresistance: a massive problem



Antimicrobial resistance collaborators, Lancet 2022, 399, p629-55



→ Approx. 4,95 millionen (3,62–6,57) death with bacterial AMR in 2019, incl. 1,27 million (95% UI 0,911–1,71) death due to bacterial AMR

# AMR in different age groups




Figure 2: Model estimates of the burden of infections with antibiotic-resistant bacteria of public health importance in DALYs, by age group, EU and European Economic Area, 2015

Error bars are 95% uncertainty intervals. DALYs=disability-adjusted life-years. \*Excludes those resistant to carbapenem or colistin. †In 2015, most of the third-generation cephalosporin-resistant *E. coli* (88·6%) and *K. pneumoniae* (85·3%) isolates reported to the European Antimicrobial Resistance Surveillance Network produced an extended-spectrum β-lactamase.<sup>9</sup>

→ the most weak in society are affected most:  
<1 year  
> 65 years

Cassini A, Diaz Högberg L, et al. Lancet Infect Dis 2019, 19:56-66

# Most prevent resistance mechanisms





Figure 1: Infections with antibiotic-resistant bacteria, EU and European Economic Area, 2015

Diameter of bubbles represents the number of disability-adjusted life-years. ColRACI=colistin-resistant *Acinetobacter* spp. CRACI=carbapenem-resistant *Acinetobacter* spp. MDRACI=multidrug-resistant *Acinetobacter* spp. VRE=vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium*. ColREC=colistin-resistant *Escherichia coli*. CREC=carbapenem-resistant *E. coli*. 3GCREC=third-generation cephalosporin-resistant *E. coli*. ColRKP=colistin-resistant *Klebsiella pneumoniae*. CRKP=carbapenem-resistant *K. pneumoniae*. 3GCRKP=third-generation cephalosporin-resistant *K. pneumoniae*. ColRPA=colistin-resistant *Pseudomonas aeruginosa*. CRPA=carbapenem-resistant *P. aeruginosa*. MDRPA=multidrug-resistant *P. aeruginosa*. MRSA=methicillin-resistant *Staphylococcus aureus*. PRSP=penicillin-resistant *Streptococcus pneumoniae*. PMRSP=penicillin-resistant and macrolide-resistant *S. pneumoniae*.

- ESBL in *E. coli* (=3GCREC)
- ESBL in *K. pneumoniae* (=3GCRKP)
- Methicillin resistant *S. aureus*
- Carbapenem resistant *P. aeruginosa*
- Do not forget:
- Sexually transmitted diseases
- *Salmonella typhimurium*

Cassini A, Diaz Högberg L, et al. Lancet Infect Dis 2019, 19:56-66


# Antimicrobial resistance in Switzerland



ESBL increases.  
MRSA decreases.  
VRE shows local outbreaks.

# Determination of AMR in the lab

- **Phenotypic profile** e.g. microdilution, disks, e-tests, (kill-curves)



- Principle: bacterial growth in presence of an antibiotic drug<sup>1</sup>
- Complex situation: living organisms are exposed to stress, usually very rich media




- **Genotypic profile** e.g. PCR, sequencing






- Principle: Presence or Absence of a Gene linked to resistance e.g. CTX-M1 oder Oxa-48
- Usually no quantitative expression of the gene, no MICs

# Example: Porin loss of oprD in *Pseudomonas aeruginosa*

- Influx mechanisms (porins)  
e.g. Carbapenem resistance due to porin loss (oprD) with *Pseudomonas aeruginosa*



# Prediction of Phenotype from Genotype? Example of oprD in *P. aeruginosa*




Holy grail!

Biggel M, ... et Seth-Smith HMB, 2022 submitted



- 2000+ *Pseudomonas aeruginosa* genomes
- In CH: Porin loss is about 10x higher than Carbapenemases

# Research: Combination of genotype and function to predict the MIC




Biggel M, ... et Seth-Smith HMB, 2022 submitted

- 2000+ *Pseudomonas aeruginosa* genomes
- **Next idea:** AI-based analysis to learn mutations and functional implications



# How can we reduce the spread of antibiotic resistance?



## Key aspects:

- **ANTIBIOTIKA STEWARDSHIP!**
  - **DIAGNOSTIC STEWARDSHIP!**
  - One Health!
- 
- Data quality is key
  - FAIR (findable, accessible, interoperable, re-usable) data



# Take home message

- **Antibiotic resistance**
  - De novo -> by mutation and selection pressure
  - With plasmid/gene transfer and selection pressure.
- **Four basic mechanisms of resistance:**
  - Efflux pump, porin loss, modification of the target, cleavage by enzymes
- **Antibiotic Stewardship**
  - Essential in combating the development of resistance
  - Concept: One Health -> humans and animals form one unit.
  - Innovative diagnostics is key!

# THANK YOU for your attention! Questions?

- Contact:

Prof. Adrian Egli, MD PhD

Institute for Medical Microbiology, University of Zurich

Email: [aegli@imm.uzh.ch](mailto:aegli@imm.uzh.ch)



@AppliedMicrobi2

Website: [www.imm.uzh.ch](http://www.imm.uzh.ch)



**Universität  
Zürich<sup>UZH</sup>**






# Research: MALDI-TOF MS analysis to predict antibiotic resistance

- MALDI-TOF MS usually used for ID
- Collaboration:




- Re-analysis of spectrum profiles with machine learning based algorithms
- 303'195 (!) spectra
- 78 commonly used antimicrobials




Weis C, Cuénod A, ... et Egli A; Nature Medicine, 2021

# Prediction of AMR category is good, but needs more work for routine application



→Deliverable:  
Prediction of AMR directly  
from the MALDI-TOF spectrum

- Prediction of susceptibility:
- *S. aureus*: MRSA (0.8 AUC)
- *E. coli*: Ceftriaxon R (0.74 AUC)
- *K. pneumoniae*: Ceftriaxon R (0.74 AUC)



→ Next step:  
Improve algorithm  
Prospective validation of the algorithm  
Expansion to prediction of invasiveness

Weis C, Cuénod A, ... et Egli A; Nature Medicine, 2021